Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.05
-0.06 (-1.17%)
Oct 6, 2026, 9:52 AM EDT - Market open
Abeona Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Abeona Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $18.88. The average 1-year stock price forecast is 273.86% higher than the current stock price, while the lowest is $14 (+177.23%) and the highest is $30 (+494.06%).
Price Target: $18.88 (+273.86%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Abeona Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | May '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $20 | Buy | Reiterates | $20 | +296.04% | Sep 25, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $28 → $30 | Buy | Maintains | $28 → $30 | +494.06% | Sep 18, 2026 |
| Roth MKM | Roth MKM | Buy Initiates $17 | Buy | Initiates | $17 | +236.63% | Sep 17, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Reiterates $21 | Buy | Reiterates | $21 | +315.84% | Aug 14, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $17 | Buy | Maintains | $17 | +236.63% | May 14, 2026 |
Financial Forecast
Revenue This Year
52.63M
from 5.82M
Increased by 804.33%
Revenue Next Year
115.62M
from 52.63M
Increased by 119.68%
EPS This Year
-0.95
from -1.24
EPS Next Year
-0.21
from -0.95
EPS and Forward PE are based on non-GAAP adjusted numbers.